When Mark Prausnitz talks about his work as a professor, researcher, and entrepreneur, one theme comes through clearly: collaboration. 

Prausnitz, a Regents’ Professor, Regents’ Entrepreneur, and J. Erskine Love Jr. Chair in the School of Chemical and Biomolecular Engineering, is this year’s recipient of the Class of 1934 Distinguished Professor Award. 

“While I may be the focal point, it’s not a recognition of me as an individual. It’s a recognition of everything the team has done,” Prausnitz said. “I know how to do some things, but there are many things I don’t know how to do. That’s why working with others matters. You bring people together, fill in the gaps, and solve the whole problem.” 

The “some things” Prausnitz knows how to do have led to revolutionary medical innovation over a 30-year career at Georgia Tech, where he has led transformative work in microneedle drug delivery, launching 10 companies in the process. 

During that time, Prausnitz published hundreds of peer-reviewed papers, was granted dozens of patents, and advanced his work from early laboratory studies into more than 20 human clinical trials. His research has produced multiple FDA‑approved or clinically tested technologies. 

Understanding Prausnitz’s success starts with his approach to engineering in practice. Science may begin with discovery, but engineering, as he describes it, focuses on taking something uncertain and making it work. 

“One of the things that really distinguishes engineering from science is the work of problem-solving to reach an answer,” he said. “You start with something diffuse and figure out how to put all the pieces together. That to me is a hallmark of engineering.” 

That way of thinking took shape early in his life. 

Read the full story.